Epigral Ltd
Epigral Q2 FY26 earnings call: Revenue & Margins
Q2 FY26 earnings call: what management said on revenue, margins and capex.
The short version
Epigral expects volume growth in the second half (H2) of FY 2026 after a subdued first half due to monsoon and maintenance. Epigral is targeting consistent growth through capacity expansion and product diversification, aiming for a 70% revenue contribution from derivatives and specialty products.
From Epigral Ltd's Q2 FY26 earnings-call transcript · updated 16 Oct 2026.
Revenue & Sales Performance
- Epigral expects volume growth in the second half (H2) of FY 2026 after a subdued first half due to monsoon and maintenance.
- The new Chlorotoluene (CT) value chain plant, commissioned in March 2025, is expected to contribute significantly to revenue from FY 2027 onwards.
- Expansion of CPVC and Epichlorohydrin capacity is underway, targeted for commissioning by Q2 FY 2026, aiming to strengthen diversification and growth.
- Post-2028, new chemistry projects targeting import substitution and high-growth products in construction and related sectors are planned to drive growth.
2 more points from Epigral Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Epigral Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Epigral is finalizing CAPEX on CPVC and Epichlorohydrin projects, expected to complete by end of Q2 FY27.
- Chlorotoluene value chain plant commissioned in March 2025; revenue contribution expected from FY27 onwards.
- Planning a new sizable project at current complex aimed for approval soon; aligned with import substitution and targeting double-digit growth products for 10-15 years beyond FY28.
- Evaluating a second new project on newly acquired land to drive growth beyond FY28.
- Focus on expanding CPVC resin capacity to 1,50,000; compound capacity already adequate with ability for quick scaling.
2 more points from Epigral Ltd's call on capex
Create a free account to keep reading this call
Fundraising & Capital Structure
See what Epigral Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Epigral Ltd said on order book & pipeline — free account, 30 seconds.
Epigral Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹736 Cr, net profit ₹82 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Epigral's management said in earlier quarters
Others in Chemicals & Petrochemicals this season
- Gujarat Alkalies (Q2 FY26)
2,136.64 Crores (Page 21). Key investor presentation takeaways from Gujarat Alkalies & Chemicals Ltd's Q2 FY26 investor presentation — and how it ranks against
- Dynemic Products Ltd (Q2 FY26)
Quarterly revenue for Q2 FY 25-26: ₹8,935 lakhs (Page 12, 10, 5) . Key investor presentation takeaways from Dynemic Products's Q2 FY26 investor presentation — a
- Platinum Industries Ltd (Q2 FY26)
Q2FY26 Revenue from Operations (Consolidated): INR 983.8 Mn, down 1% YoY from INR 996.4 Mn in Q2FY25. Key investor presentation takeaways from Platinum Industri
- IVP Ltd (Q2 FY26)
Revenue from Operations for Q2FY26: ₹146.95 crores . Key investor presentation takeaways from IVP's Q2 FY26 investor presentation — and how it ranks against sec
Potential multibaggers · Q2 FY27
This quarter's potential multibaggers
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Epigral Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Epigral Ltd Q2 FY26 results?
Epigral expects volume growth in the second half (H2) of FY 2026 after a subdued first half due to monsoon and maintenance. Epigral is targeting consistent growth through capacity expansion and product diversification, aiming for a 70% revenue contribution from derivatives and specialty products.
What is Epigral Ltd share price analysis?
Epigral Ltd currently shows a neutral. The stock trades at a P/E of 15.8 with a market cap of ₹4,296 Cr. Investors should review the full earnings analysis for detailed insights.
Is Epigral Ltd planning capital expenditure?
Epigral is finalizing CAPEX on CPVC and Epichlorohydrin projects, expected to complete by end of Q2 FY27.
Keep Epigral Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.